Lucan · Conditions

Menopausal symptoms

Australian guidance: RANZCOG C-Gyn 9 Managing Menopausal Symptoms (2020) + AMS

1. Definition and epidemiology

Menopause is defined as the final menstrual period, confirmed retrospectively after 12 consecutive months of amenorrhoea, representing the permanent cessation of ovarian follicular activity. The average age of natural menopause in Australia is 51 years, with the perimenopause transition commonly starting around age 47. Menopause before age 40 is classified as premature ovarian insufficiency and before age 45 as early menopause; around 80% of women experience symptoms during the menopause transition, and approximately 25% have symptoms severe enough to require medical intervention.

2. Pathophysiology

The ovary contains a finite primordial follicle pool that undergoes progressive atresia throughout reproductive life. As women approach the fifth decade, follicle numbers fall below a critical threshold, granulosa cell mass diminishes, and inhibin B secretion drops. The consequent loss of negative feedback on the hypothalamus and anterior pituitary drives a compensatory rise in follicle stimulating hormone (FSH) and luteinising hormone (LH). Oestradiol levels become erratic during perimenopause before falling to persistently low postmenopausal concentrations. This oestrogen deficiency is the proximate driver of vasomotor symptoms (VMS) via altered central thermoregulatory set points in the hypothalamus, particularly through kisspeptin and neurokinin B neurones in the arcuate nucleus. Urogenital atrophy results from oestrogen receptor loss in vaginal and urethral epithelium, leading to thinning, reduced lubrication, and altered vaginal flora. Bone remodelling shifts toward net resorption as osteoclast activity is no longer suppressed by oestrogen, accelerating trabecular bone loss and increasing fracture risk. Robbins Ch 22 describes the histological sequence of ovarian involution and the endometrial atrophy that accompanies postmenopausal oestrogen withdrawal.

3. Clinical presentation and diagnostic criteria

The diagnosis of menopause is clinical, based on 12 months of amenorrhoea in a woman over 45 without another identifiable cause. During perimenopause, cycle length variability of 7 days or more signals the early transition; amenorrhoea of 60 days or more signals the late transition. The dominant presenting symptoms are vasomotor: hot flushes and night sweats, which typically last 4 to 5 years but persist beyond a decade in around 10% of women. Genitourinary syndrome of menopause (GSM) includes vaginal dryness, dyspareunia, urinary frequency and recurrent urinary tract infections. Sleep disturbance, low mood, anxiety, cognitive fogginess, joint pains, and reduced libido are common. Physical examination may reveal vaginal atrophy, pale thin epithelium, and reduced rugal folding. Elevated FSH and low oestradiol on two separate occasions can confirm menopause in women under 45 or when the diagnosis is uncertain; anti-Mullerian hormone (AMH) is not recommended for diagnostic purposes.

4. Investigations and AU-specific cutoffs

Investigations are not required to diagnose menopause in women over 45 with 12 months of amenorrhoea and typical symptoms. In women under 45 or where clinical uncertainty exists, measure FSH and oestradiol on two occasions at least 4 to 6 weeks apart; FSH above 40 IU/L with oestradiol below 100 pmol/L on two samples supports premature ovarian insufficiency. Thyroid stimulating hormone (TSH) should be checked to exclude hypothyroidism as a contributing cause of fatigue, weight gain, and menstrual irregularity. A full blood count helps exclude iron deficiency anaemia causing fatigue in the context of heavy perimenopausal bleeding. Lipid profile and fasting glucose assess cardiovascular and metabolic risk that rises after menopause. Bone mineral density via Dual X-ray Absorptiometry (DXA) is indicated in women with premature or early menopause, prolonged amenorrhoea, or additional osteoporosis risk factors; fracture risk stratification can be estimated using the FRAX tool. Cardiovascular risk assessment should be guided by age and established risk factors per Heart Foundation guidance. Cervical screening (via Cervical Screening Test at 5-yearly intervals in Australian women aged 25 to 74) and biennial breast screen (BreastScreen Australia from age 50) should be maintained at this consultation.

5. Management

Management is individualised, beginning with lifestyle counselling for all women regardless of symptom severity. Lifestyle measures recommended by RANZCOG C-Gyn 9 include regular weight-bearing exercise, stress reduction, calcium and vitamin D optimisation, smoking cessation, and reduction of excessive alcohol and caffeine intake. Sexual counselling for the woman and her partner should be offered when GSM affects intimacy.

Menopausal hormone therapy (MHT) is the most effective treatment for troublesome VMS and urogenital atrophy and is the principal pharmacological intervention. For women with an intact uterus, combined oestrogen plus progestogen is mandatory to prevent unopposed oestrogen-induced endometrial hyperplasia; oestrogen alone is reserved for women post-hysterectomy. Dosing begins low and titrates to symptom relief. MHT should be commenced within 10 years of the final menstrual period where possible (the "window of opportunity"); initiation after age 60 is generally not recommended as the benefit-risk balance becomes unfavourable. Women with premature or early menopause should receive MHT until at least age 50 unless contraindicated.

For women with isolated vaginal symptoms, local vaginal oestrogen (pessary, tablet, cream, or ring) is the preferred option and does not require concomitant progestogen even in women with an intact uterus. Bioidentical compounded hormone preparations are not recommended due to absence of standardised composition and inadequate safety data.

Non-hormonal pharmacological options are available for women who cannot use or decline MHT, including those with a personal history of breast cancer or prior venous thromboembolism (VTE). These include low-dose selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), and gabapentin for VMS. Note that paroxetine and fluoxetine are contraindicated in women taking tamoxifen as they inhibit CYP2D6 and reduce tamoxifen conversion to its active metabolite endoxifen.

6. Pharmacology and AU PBS notes

Systemic oestrogen preparations available in Australia include oral conjugated equine oestrogen (Premarin), micronised oestradiol (Estrofem, Zumenon), oestradiol valerate (Progynova), and transdermal oestradiol patches (Estradot, Climara) and gel (Sandrena, Estrogel). Transdermal routes are preferred in women with obesity, migraine, elevated VTE risk, or hepatic impairment because they bypass hepatic first-pass metabolism and do not increase VTE risk in low-risk women.

Progestogens for endometrial protection include micronised progesterone (Prometrium, Utrogestan) and synthetic progestins. Combined oral preparations include Kliovance (low-dose continuous combined) and Femoston (cyclical or continuous). The levonorgestrel-releasing intrauterine system (Mirena, PBS listed for heavy menstrual bleeding) provides endometrial protection during perimenopausal systemic oestrogen use.

Tibolone (Livial) is a synthetic steroid with mixed oestrogenic, progestogenic, and weak androgenic activity; it is effective for VMS and urogenital atrophy but is restricted to women more than 12 months postmenopause due to risk of irregular bleeding. It increases risk of breast cancer recurrence and should not be used in women with prior breast cancer; it also increases stroke risk in women over 65.

Non-hormonal VMS options: venlafaxine 37.5 to 75 mg daily (PBS listed for depression), escitalopram 10 to 20 mg daily, or gabapentin 300 mg nocte titrating to effect. These are not PBS-listed specifically for menopause. Clonidine has limited efficacy and is rarely used.

PBS note: MHT preparations are generally authority-listed or unrestricted PBS items depending on the specific product; prescribers should verify current PBS status as listing changes with formulary updates. No menopausal indication-specific streamlined code applies.

7. Complications and monitoring

Key complications of untreated menopause include accelerated bone loss leading to osteoporosis and fragility fracture, increased cardiovascular risk from lipid redistribution and vascular endothelial changes, and urogenital atrophy causing recurrent infections and sexual dysfunction. Mental health complications include an increased risk of anxiety and depressive disorders, particularly in women with prior affective disorders, premature or surgical menopause, or concurrent chronic sleep disturbance.

Key complications of MHT that require surveillance:

Breast cancer risk increases with duration of combined MHT use; the absolute increase is modest but persistence after cessation has been reported. Annual review of MHT is recommended; continuation beyond 5 to 7 years requires explicit individual risk-benefit discussion. Women on MHT should have biennial mammography as per BreastScreen Australia protocol.

VTE risk is increased approximately 2-fold with oral combined MHT, greatest in the first year of use. Prior personal history of VTE is a contraindication to oral MHT; transdermal routes can be considered with specialist input. Oral MHT should not be used for primary cardiovascular disease prevention.

Endometrial risk from unopposed oestrogen necessitates progestogen co-prescription in all women with an intact uterus. Unscheduled vaginal bleeding beyond the first 6 months of continuous combined therapy requires investigation with transvaginal ultrasound and possible endometrial biopsy.

Surveillance schedule: review at 6 months post-initiation (clinical assessment, blood pressure, breast check, symptom response), then 6 to 12 monthly thereafter. DXA at 2 yearly intervals for women on therapy for osteoporosis protection or with bone density concern. FRAX recalculation every 1 to 2 years in higher-risk patients.

Written for Australian practice and grounded in the guidance named above. Study material only — not medical advice. Always check against current guidelines.